Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Kenemans

Showing results (181-190 of 235) with videos related to

Pageof 24
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 1, 1992
Radioimmunotargeting in ovarian carcinoma patients with indium-111 labeled monoclonal antibody OV-TL 3 F(ab')2: pharmacokinetics, tissue distribution, and tumor imagingM.R. Buist, P. Kenemans, J.B. Vermorken, et al.
Fertility and Sterility|April 15, 1999
Long-term effects of combined hormone replacement therapy on markers of endothelial function and inflammatory activity in healthy postmenopausal womenW M van Baal, P Kenemans, J J Emeis, et al.
British Journal of Obstetrics and Gynaecology|July 30, 1999
An immunoscintigraphic evaluation of the engineered human monoclonal antibody (hCTMO1) for use in the treatment of ovarian carcinomaQ Davies, A C Perkins, J C Roos, et al.
Anticancer Research|November 1, 1991
Biodistribution of iodine-125 and indium-111 labeled OV-TL 3 intact antibodies and F(ab')2 fragments in tumor-bearing athymic miceL F Massuger, O C Boerman, F H Corstens, et al.
Gynecologic Oncology|March 1, 1993
HPV DNA presence and HPV genotypes as prognostic factors in low-stage squamous cell cervical cancerP F van Bommel, A J van den Brule, T J Helmerhorst, et al.
Cancer Research|November 15, 1993
Kinetics and tissue distribution of the radiolabeled chimeric monoclonal antibody MOv18 IgG and F(ab')2 fragments in ovarian carcinoma patientsM R Buist, P Kenemans, W den Hollander, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|July 3, 1999
Influence of chemotherapy on the expression of p53, HER-2/neu and proliferation markers in ovarian cancerH W Nijman, P Kenemans, R J Poort-Keesom, et al.
European Journal of Clinical Investigation|December 3, 1999
Short-term hormone replacement therapy: reduced plasma levels of soluble adhesion moleculesW M Van Baal, J J Emeis, P Kenemans, et al.
Gynecologic Oncology|January 6, 2000
Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutationsR P Zweemer, P J van Diest, R H Verheijen, et al.
British Journal of Cancer|June 1, 1993
Analysis of MHC class I and II expression in relation to presence of HPV genotypes in premalignant and malignant cervical lesionsF V Cromme, C J Meijer, P J Snijders, et al.
Pageof 24

Showing results (181-190 of 235) with videos related to

Sort By:
Pageof 24
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 1, 1992
Radioimmunotargeting in ovarian carcinoma patients with indium-111 labeled monoclonal antibody OV-TL 3 F(ab')2: pharmacokinetics, tissue distribution, and tumor imagingM.R. Buist, P. Kenemans, J.B. Vermorken, et al.
Fertility and Sterility|April 15, 1999
Long-term effects of combined hormone replacement therapy on markers of endothelial function and inflammatory activity in healthy postmenopausal womenW M van Baal, P Kenemans, J J Emeis, et al.
British Journal of Obstetrics and Gynaecology|July 30, 1999
An immunoscintigraphic evaluation of the engineered human monoclonal antibody (hCTMO1) for use in the treatment of ovarian carcinomaQ Davies, A C Perkins, J C Roos, et al.
Anticancer Research|November 1, 1991
Biodistribution of iodine-125 and indium-111 labeled OV-TL 3 intact antibodies and F(ab')2 fragments in tumor-bearing athymic miceL F Massuger, O C Boerman, F H Corstens, et al.
Gynecologic Oncology|March 1, 1993
HPV DNA presence and HPV genotypes as prognostic factors in low-stage squamous cell cervical cancerP F van Bommel, A J van den Brule, T J Helmerhorst, et al.
Cancer Research|November 15, 1993
Kinetics and tissue distribution of the radiolabeled chimeric monoclonal antibody MOv18 IgG and F(ab')2 fragments in ovarian carcinoma patientsM R Buist, P Kenemans, W den Hollander, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|July 3, 1999
Influence of chemotherapy on the expression of p53, HER-2/neu and proliferation markers in ovarian cancerH W Nijman, P Kenemans, R J Poort-Keesom, et al.
European Journal of Clinical Investigation|December 3, 1999
Short-term hormone replacement therapy: reduced plasma levels of soluble adhesion moleculesW M Van Baal, J J Emeis, P Kenemans, et al.
Gynecologic Oncology|January 6, 2000
Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutationsR P Zweemer, P J van Diest, R H Verheijen, et al.
British Journal of Cancer|June 1, 1993
Analysis of MHC class I and II expression in relation to presence of HPV genotypes in premalignant and malignant cervical lesionsF V Cromme, C J Meijer, P J Snijders, et al.
Pageof 24